BR112017021098A2 - método para prever risco de deterioração cognitiva - Google Patents
método para prever risco de deterioração cognitivaInfo
- Publication number
- BR112017021098A2 BR112017021098A2 BR112017021098A BR112017021098A BR112017021098A2 BR 112017021098 A2 BR112017021098 A2 BR 112017021098A2 BR 112017021098 A BR112017021098 A BR 112017021098A BR 112017021098 A BR112017021098 A BR 112017021098A BR 112017021098 A2 BR112017021098 A2 BR 112017021098A2
- Authority
- BR
- Brazil
- Prior art keywords
- cognitive impairment
- patient
- predict risk
- progression
- methods
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0048—Detecting, measuring or recording by applying mechanical forces or stimuli
- A61B5/0055—Detecting, measuring or recording by applying mechanical forces or stimuli by applying suction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
- A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/40—Detecting, measuring or recording for evaluating the nervous system
- A61B5/4076—Diagnosing or monitoring particular conditions of the nervous system
- A61B5/4088—Diagnosing of monitoring cognitive diseases, e.g. Alzheimer, prion diseases or dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4842—Monitoring progression or stage of a disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7271—Specific aspects of physiological measurement analysis
- A61B5/7275—Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
- A61B5/14507—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue specially adapted for measuring characteristics of body fluids other than blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/40—Detecting, measuring or recording for evaluating the nervous system
- A61B5/4058—Detecting, measuring or recording for evaluating the nervous system for evaluating the central nervous system
- A61B5/4064—Evaluating the brain
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/775—Apolipopeptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medical Informatics (AREA)
- Neurology (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physiology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Psychology (AREA)
- Computer Vision & Pattern Recognition (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2015901210A AU2015901210A0 (en) | 2015-04-02 | Method for predicting risk of cognitive deterioration | |
| AU2016900347A AU2016900347A0 (en) | 2016-02-03 | Method for predicting risk of cognitive deterioration | |
| PCT/AU2016/050248 WO2016154682A1 (en) | 2015-04-02 | 2016-04-01 | Method for predicting risk of cognitive deterioration |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112017021098A2 true BR112017021098A2 (pt) | 2018-07-03 |
Family
ID=57003726
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017021098A BR112017021098A2 (pt) | 2015-04-02 | 2016-04-01 | método para prever risco de deterioração cognitiva |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20180284141A1 (enExample) |
| EP (1) | EP3278113A4 (enExample) |
| JP (1) | JP2018513368A (enExample) |
| KR (1) | KR20170132318A (enExample) |
| CN (1) | CN107636468A (enExample) |
| AU (1) | AU2016240409A1 (enExample) |
| BR (1) | BR112017021098A2 (enExample) |
| CA (1) | CA2981533A1 (enExample) |
| WO (1) | WO2016154682A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6783864B2 (ja) | 2016-01-22 | 2020-11-11 | シナプティヴ メディカル (バルバドス) インコーポレイテッドSynaptive Medical (Barbados) Inc. | 磁気共鳴画像法を使用した磁場に依存するリラクソメトリーのためのシステムおよび方法 |
| WO2018064715A1 (en) * | 2016-10-03 | 2018-04-12 | Crc For Mental Health Ltd | Method for predicting or diagnosing cognitive deterioration |
| US11690560B2 (en) | 2016-10-24 | 2023-07-04 | Akili Interactive Labs, Inc. | Cognitive platform configured as a biomarker or other type of marker |
| US20190265256A1 (en) * | 2016-11-02 | 2019-08-29 | Kyushu University, National University Corporation | Method for determining alzheimer's disease risk |
| EP3555841A4 (en) | 2016-12-13 | 2020-05-20 | Akili Interactive Labs, Inc. | BIOMARKER IDENTIFICATION PLATFORM USING NAVIGATION TASKS AND TREATMENTS USING NAVIGATION TASKS |
| WO2018148788A1 (en) * | 2017-02-17 | 2018-08-23 | Crc For Mental Health Ltd | Method for predicting risk and rate of amyloid deposition and plaque formation |
| WO2018176082A1 (en) * | 2017-03-28 | 2018-10-04 | Crc For Mental Health Ltd | Predicting progression of cognitive deterioration |
| JP6199520B1 (ja) * | 2017-04-11 | 2017-09-20 | 株式会社アルム | 保険管理装置、および保険管理システム |
| WO2018204404A1 (en) * | 2017-05-01 | 2018-11-08 | Rhode Island Hospital | Non-invasive measurement to predict post-surgery anterior cruciate ligament success |
| KR102076091B1 (ko) * | 2017-08-30 | 2020-02-11 | 사회복지법인 삼성생명공익재단 | 기억성 경도인지장애(aMCI) 환자에 대한 아밀로이드 페트 검사 양성률 예측 방법 및 장치 |
| EP3861352A4 (en) * | 2018-10-04 | 2022-08-03 | University of Manitoba | NOVEL BIOMARKER FOR HUMAN ALZHEIMER'S DISEASE |
| CN109464122B (zh) * | 2018-11-05 | 2022-02-18 | 西南大学 | 基于多模态数据的个体核心特质预测系统及方法 |
| WO2020261608A1 (ja) * | 2019-06-28 | 2020-12-30 | 株式会社島津製作所 | アミロイドβの脳内蓄積状態評価方法及び評価装置 |
| JP2022545083A (ja) * | 2019-08-20 | 2022-10-25 | テラン バイオサイエンシズ, インコーポレイテッド | パーキンソン病を評価するためのニューロメラニン高感度mri |
| JPWO2021039941A1 (enExample) * | 2019-08-30 | 2021-03-04 | ||
| US11798652B2 (en) | 2020-08-24 | 2023-10-24 | Kpn Innovations, Llc. | Method of and system for identifying and ameliorating body degradations |
| US11416776B2 (en) | 2020-08-24 | 2022-08-16 | Kpn Innovations, Llc. | Method of and system for identifying and enumerating cross-body degradations |
| US11179110B1 (en) | 2020-08-31 | 2021-11-23 | Kpn Innovations Llc | Method of system for reversing inflammation in a user |
| CN112526132A (zh) * | 2020-11-23 | 2021-03-19 | 华中科技大学 | 预测2型糖尿病患者出现记忆力衰退的风险的方法 |
| CN112353381B (zh) * | 2020-11-24 | 2022-06-28 | 杭州冉曼智能科技有限公司 | 基于多模态大脑影像的阿尔茨海默症综合诊断系统 |
| KR102406900B1 (ko) | 2021-08-19 | 2022-06-08 | 의료법인 명지의료재단 | 노인 상태 개선 방법 및 시스템 |
| KR102607398B1 (ko) * | 2022-01-19 | 2023-11-29 | 이화여자대학교 산학협력단 | 뇌연령에 기초한 연령 관련 인지 저하 모니터링 방법 및 장치 |
| CN114724709B (zh) * | 2022-06-07 | 2022-10-14 | 深圳市铱硙医疗科技有限公司 | 基于vr眼动追踪的痴呆风险筛查系统、设备及介质 |
| KR102771596B1 (ko) * | 2022-07-14 | 2025-02-24 | 이화여자대학교 산학협력단 | 뇌영상으로부터 뇌성별 및 뇌연령을 예측하는 방법 및 장치 |
| CN120089387B (zh) * | 2025-05-07 | 2025-07-15 | 脑玺(苏州)智能科技有限公司 | 超早期认知下降状态的识别方法、装置及电子设备 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL154093A0 (en) * | 2000-07-25 | 2003-07-31 | Sir Mortimer B Davis Jewish Ge | Ho-1 suppressor as a diagnostic and prognostic test for dementing diseases |
| EP1355933A2 (en) * | 2000-08-04 | 2003-10-29 | Loma Linda University Medical Center | Iron regulating protein-2 (irp-2) as a diagnostic for neurodegenerative diseases |
| AU2003251920A1 (en) * | 2002-07-12 | 2004-02-02 | The Buck Institute For Research On Aging | Iron sequestration or elimination to reduce neurodegeneration or parkinsons disease progression |
| US20040102692A1 (en) * | 2002-11-27 | 2004-05-27 | General Electric Company | Magnetic resonance imaging system and methods for the detection of brain iron deposits |
| US20050020904A1 (en) * | 2003-07-10 | 2005-01-27 | Cline Harvey Ellis | System and method for the detection of brain iron using magnetic resonance imaging |
| US7728038B2 (en) * | 2004-08-04 | 2010-06-01 | University Of Utah Research Foundation | Methods for chelation therapy |
| US20110236917A1 (en) * | 2009-11-17 | 2011-09-29 | Power3 Medical Products, Inc. | Diagnosis of Alzheimer's Disease |
| WO2012027794A2 (en) * | 2010-09-01 | 2012-03-08 | The Mental Health Research Institute Of Victoria | Method of treatment and agents useful for same |
| CN102743365A (zh) * | 2011-04-19 | 2012-10-24 | 辽宁省计划生育科学研究院 | 一种化合物或其药学上可接受的盐在防治老年痴呆的应用 |
| JP6084976B2 (ja) * | 2011-09-06 | 2017-02-22 | ユニバーシティ オブ フロリダ リサーチ ファウンデーション インコーポレイテッド | 組織内の異常物質の存在を検出するシステム及び方法 |
| CN103251932A (zh) * | 2013-04-17 | 2013-08-21 | 钱忠明 | 铁调素在制备铁相关神经退行性疾病药物中的应用 |
-
2016
- 2016-04-01 CA CA2981533A patent/CA2981533A1/en not_active Abandoned
- 2016-04-01 AU AU2016240409A patent/AU2016240409A1/en not_active Abandoned
- 2016-04-01 EP EP16771103.5A patent/EP3278113A4/en not_active Withdrawn
- 2016-04-01 JP JP2017551127A patent/JP2018513368A/ja active Pending
- 2016-04-01 CN CN201680032358.XA patent/CN107636468A/zh active Pending
- 2016-04-01 US US15/562,801 patent/US20180284141A1/en not_active Abandoned
- 2016-04-01 KR KR1020177031704A patent/KR20170132318A/ko not_active Withdrawn
- 2016-04-01 BR BR112017021098A patent/BR112017021098A2/pt not_active Application Discontinuation
- 2016-04-01 WO PCT/AU2016/050248 patent/WO2016154682A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| KR20170132318A (ko) | 2017-12-01 |
| CN107636468A (zh) | 2018-01-26 |
| EP3278113A4 (en) | 2018-11-21 |
| JP2018513368A (ja) | 2018-05-24 |
| AU2016240409A1 (en) | 2017-11-09 |
| EP3278113A1 (en) | 2018-02-07 |
| CA2981533A1 (en) | 2016-10-06 |
| US20180284141A1 (en) | 2018-10-04 |
| WO2016154682A1 (en) | 2016-10-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112017021098A2 (pt) | método para prever risco de deterioração cognitiva | |
| IL288712A (en) | Methods for treating abnormal movement disorders | |
| IL281566A (en) | Methods and systems for diagnosing and treating health ailments | |
| EP3397139C0 (en) | DEVICE, SYSTEM AND METHOD FOR NON-INVASIVE CONTROL OF PHYSIOLOGICAL MEASUREMENTS | |
| MX2023000563A (es) | Metodos y procesos para evaluacion no invasiva de variaciones geneticas. | |
| HK1211085A1 (zh) | 治療缺鐵性貧血的方法 | |
| SG11201802145SA (en) | Novel lactobacillus and composition for preventing, improving, or treating degenerative brain diseases or cognitive function disorders | |
| FI20145492A7 (fi) | Menetelmä Parkinsonin taudin diagnostiikkaan, hoitoon ja estämiseen | |
| BR112017009159A2 (pt) | métodos e biomarcadores para predizer a eficácia e avaliação de um tratamento com agonista de ox40 | |
| MX378789B (es) | Métodos y composiciones para tratar la enfermedad de huntington. | |
| MX376201B (es) | Compuestos inhibidores de metaloenzima. | |
| IL257747B (en) | Methods of diagnosing and treating anxiety disorder | |
| EP2981252A4 (en) | Methods of treating diseases characterized by excessive wnt signalling | |
| WO2017066712A3 (en) | Modulators of telomere disease | |
| JO3516B1 (ar) | مُعدِّلات بنزإيميدازول-2-يل بيريميدين لمستقبل الهستامين h4 | |
| SG11201700530PA (en) | Agent for improving brain function and agent for preventing or treating cognitive impairment | |
| IL250213B (en) | A method for treating cognitive or emotional impairment related to radiotherapy and chemotherapy with cannabinoids | |
| SG11201703856VA (en) | Method for treating, preventing, or reducing the risk of skin infection | |
| HK1254637A1 (zh) | 使用slit2识别、评估、预防及治疗代谢疾病的方法 | |
| EP3274709A4 (en) | Biomarkers and methods of diagnosing and prognosing mild traumatic brain injuries | |
| TR201900665T4 (tr) | Diyabetik nefropatinin tedavi yöntemi. | |
| EP2914270A4 (en) | MEDIUM TO AVOID OR IMPROVE RECOVERIES OF THE BRAIN FUNCTION | |
| EP2866565A4 (en) | METHOD FOR TREATING, DIAGNOSIS AND / OR MONITORING THE PROGRESSION OF OXO ASSOCIATED STATES | |
| MX2016007716A (es) | Metodos para el tratamiento de trastornos cerebrales o la identificacion de biomarcadores relacionados con estos. | |
| BR112016029661A2 (pt) | retosiban para tratamento de parto prematuro |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |